ECE2013 Poster Presentations Female reproduction (47 abstracts)
Value of lipid accumulation product for the assessment of metabolic syndrome in women with polycystic ovary syndrome
Ivana Bozic Antic 1 , Jelica Bjekic-Macut 2 , Dimitrios Panidis 3 , Danijela Vojnovic Milutinovic 4 , Biljana Kastratovic 5 , Milan Petakov 1 , Bojana Popovic 1 , Sanja Ognjanovic 1 , Tamara Bogavac 1 , Tatjana Isailovic 1 , Valentina Elezovic 1 , Dusan Ilic 1 & Djuro Macut 1
1Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 2Clinical-Hospital Center “Bežanijska kosa”, Belgrade, Serbia; 3Division of Endocrinology and Human Reproduction, 2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4Institute for Biologic Investigations ”Siniša Stanković“, Belgrade, Serbia; 5Clinic for Obstetrics and Gynecology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Introduction: Women with polycystic ovary syndrome (PCOS) have higher prevalence of metabolic syndrome (MS) than healthy, age and BMI matched women. The aim of this study was to determine if novel abdominal adiposity index – lipid accumulation product (LAP), could predict MS in women with PCOS.
Methods: PCOS was diagnosed using ESHRE/ASRM criteria. We evaluated 218 non-obese PCOS women (PCOS group: 22.4±3.6 kg/m2; 24.8±4.6 years) and 44 non-obese, BMI-matched healthy women (control group: 21.3±3.2 kg/m2; 28.4±4.9 years). MS was diagnosed according to JIS criteria (waist circumference cut off 80 cm) in 29/218 (13%) PCOS women, while no woman in controls group had MS. PCOS group was divided into subgroups: PCOS with MS (27.3±2.8 kg/m2; 27.4±6.2 years) and PCOS without MS (21.6±3.0 kg/m2; 24.3±4.2 years). In all subjects blood pressure (BP) and waist circumference (WC) were determined. Blood samples were collected in follicular phase of menstrual cycle for determination of basal glucose, insulin, HDL-cholesterol, triglycerides, testosterone, SHBG and DHEAS. Systolic and diastolic BP (SBP and DBP, respectively) were determined. LAP was calculated using formula ((WC-58)×triglycerides). Homeostatic model (HOMA) index and free androgen index (FAI) were also calculated using standard formula.
Results: There was no difference in LAP between PCOS and controls (20.4±19.3 vs 18.2±23.5, P=0.27). PCOS without MS had significantly lower LAP than PCOS with MS (15.4±12.4 vs 51.6±26.2, P<0.001) and there was no difference in LAP between PCOS without MS and controls (P=0.56). In PCOS group LAP correlated with HOMA (r=0.29, P<0.001), FAI (r=0.40, P<0.001), SBP (r=0.26, P<0.001), DBP (r=0.23, P<0.001). JIS criteria for MS, FAI and LAP entered binary logistic regression analysis which showed that independent predictors for MS in PCOS group were LAP (P=0.002), SBP (P=0.001) and HDL-cholesterol (P=0.001).
Conclusion: LAP is useful surrogate marker for the assessment of MS in women with PCOS.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more